How does RIG2's PE Ratio compare to its peers?

RIG2 is good value based on its Price-To-Earnings Ratio (9.2x) compared to the peer average (22.8x).

How does RIG2's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

RIG2 is good value based on its Price-To-Earnings Ratio (9.2x) compared to the European Pharmaceuticals industry average (20.3x).

What is RIG2's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RIG2 is good value based on its Price-To-Earnings Ratio (9.2x) compared to the estimated Fair Price-To-Earnings Ratio (17.6x).

What is the Fair Price of RIG2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

RIG2 (€26.48) is trading below our estimate of [[fair value]] (€72.77)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is less than 20% higher than the current share price.

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt (DB:RIG2) - Stock Price, News & Analysis

RIG2 Stock Overview

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. More details

RIG2 fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	3/6
Past Performance	5/6
Financial Health	5/6
Dividends	4/6

Rewards

Trading at 63.6% below our estimate of its fair value

Earnings are forecast to grow 14.22% per year

Earnings grew by 121.5% over the past year

Trading at good value compared to peers and industry

Risk Analysis

Unstable dividend track record

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Competitors

Dermapharm Holding

XTRA:DMP

€2.0b

Merck KGaA

XTRA:MRK

€62.2b

PharmaSGP Holding

XTRA:PSG

€287.8m

Pierrel

DB:2FJ0

€92.8m

Price History & Performance

Summary of all time highs, changes and price drops for Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
Historical stock prices
Current Share Price	Ft26.48
52 Week High	Ft28.32
52 Week Low	Ft21.90
Beta	0.35
11 Month Change	-3.71%
3 Month Change	-1.41%
1 Year Change	19.28%
33 Year Change	14.63%
5 Year Change	50.11%
Change since IPO	308.01%

Recent updates

Shareholder Returns

	RIG2	DE Pharmaceuticals	DE Market
7D	1.8%	1.4%	0.8%
1Y	19.3%	-18.4%	9.1%

Return vs Industry: RIG2 exceeded the German Pharmaceuticals industry which returned -19.3% over the past year.

Return vs Market: RIG2 exceeded the German Market which returned 8.5% over the past year.

Price Volatility

Is RIG2's price volatile compared to industry and market?
RIG2 volatility
RIG2 Average Weekly Movement	3.9%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: RIG2 has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: RIG2's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1901	11,603	Gabor Orban	www.gedeonrichter.com/hu-hu

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. researches, develops, manufactures, markets, and sells pharmaceutical products worldwide. It operates through two segments, Pharmaceuticals, and Wholesale and Retail.

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Fundamentals Summary

How do Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt's earnings and revenue compare to its market cap?
RIG2 fundamental statistics
Market cap	€4.73b
Earnings (TTM)	€516.70m
Revenue (TTM)	€2.05b

9.2x

P/E Ratio

2.3x

P/S Ratio

Is RIG2 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RIG2 income statement (TTM)
Revenue	Ft839.60b
Cost of Revenue	Ft269.96b
Gross Profit	Ft569.64b
Other Expenses	Ft358.00b
Earnings	Ft211.64b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	1.16k
Gross Margin	67.85%
Net Profit Margin	25.21%
Debt/Equity Ratio	5.4%

How did RIG2 perform over the long term?

See historical performance and comparison

Dividends

4.1%

Current Dividend Yield

35%

Payout Ratio

RIG2 Stock Overview

Rewards

Risk Analysis

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Competitors

XTRA:DMP

€2.0b

XTRA:MRK

€62.2b

XTRA:PSG

€287.8m

DB:2FJ0

€92.8m

Price History & Performance

Recent News & Updates

Third quarter 2024 earnings released: EPS: Ft203 (vs Ft294 in 3Q 2023)

Second quarter 2024 earnings released: EPS: Ft383 (vs Ft155 in 2Q 2023)

Upcoming dividend of Ft423 per share

High number of new directors

First quarter 2024 earnings released: EPS: Ft373 (vs Ft210 in 1Q 2023)

Dividend of Ft423 announced

Recent updates

Third quarter 2024 earnings released: EPS: Ft203 (vs Ft294 in 3Q 2023)

Second quarter 2024 earnings released: EPS: Ft383 (vs Ft155 in 2Q 2023)

Upcoming dividend of Ft423 per share

High number of new directors

First quarter 2024 earnings released: EPS: Ft373 (vs Ft210 in 1Q 2023)

Dividend of Ft423 announced

High number of new directors

Full year 2023 earnings released: EPS: Ft860 (vs Ft907 in FY 2022)

Full year 2023 earnings released: EPS: Ft860 (vs Ft835 in FY 2022)

Third quarter 2023 earnings released: EPS: Ft294 (vs Ft442 in 3Q 2022)

European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis

Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®

Gedeon Richter and Sumitomo Pharma Receives Positive Chmp Opinion for Ryeqo(R) for Treatment of Endometriosis

Gedeon Richter and Sumitomo Pharma Receives Positive Chmp Opinion for Ryeqo(R) for Treatment of Endometriosis

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: Ft155 (vs Ft411 in 2Q 2022)

Upcoming dividend of Ft390 per share at 4.5% yield

First quarter 2023 earnings released: EPS: Ft210 (vs Ft199 in 1Q 2022)

Full year 2022 earnings released

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired OC Distributors Ltd from Consilient Health for £32.5 million.

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. to Report Q1, 2023 Results on May 12, 2023

No independent directors

Second quarter 2022 earnings released: EPS: Ft411 (vs Ft151 in 2Q 2021)

Upcoming dividend of Ft225 per share

Investor sentiment improved over the past week

No independent directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS Ft205 (vs Ft121 in 3Q 2020)

Second quarter 2021 earnings released: EPS Ft151 (vs Ft170 in 2Q 2020)

Upcoming dividend of Ft225 per share

First quarter 2021 earnings released: EPS Ft145 (vs Ft156 in 1Q 2020)

New 90-day high: €24.26

Felicia Group agreed to acquire wholesale and retail operations from Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER).

New 90-day high: €21.42

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) completed the acquisition of Outside US Evra® transdermal contraceptive patch assets of Janssen Pharmaceutica NV.

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. to Report First Half, 2021 Results on Aug 03, 2021

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) signed an asset purchase agreement to acquire Outside US Evra® transdermal contraceptive patch assets of Janssen Pharmaceutica NV for approximately $260 million.

New 90-day high: €20.34

New 90-day low: €17.66

Univfy Inc. and Gedeon Richter Announce Partnership to Launch Personalized in Vitro Fertilization Counselling Platform to Support Fertility Patients and Providers in Europe

New 90-day low - €17.51

Shareholder Returns

Price Volatility

About the Company

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Fundamentals Summary

9.2x

2.3x

Earnings & Revenue

Dividends

4.1%

35%